Target intelligence / Profile preview

Leptin signaling pathway

Molecular classification: IL6-type class I cytokine receptor family

Overview

The Leptin signaling pathway is a complex molecular signaling cascade crucial for energy homeostasis and various physiological processes. Initiated by leptin binding to its receptor (LepRb, the primary signaling form), it lacks intrinsic kinase activity and relies on cytoplasmic kinases like JAK2. Key activated pathways include JAK/STAT, PI3K, MAPK, and AMPK/ACC. Regulation involves negative feedback by SOCS3 and modulation by adaptor proteins like SH2B1. Disruptions in this pathway are implicated in obesity, metabolic disorders, and other conditions, making it a significant therapeutic target.

Biological functions

Energy homeostasisGlucose metabolismReproductionBone homeostasisImmune signalingAngiogenesisHematopoiesis

Disease associations

ObesityMetabolic disordersType 1 diabetesImmune-related disorders

Beyond the preview

Go deeper on Leptin signaling pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leptin signaling pathway.

Explore the full profile